New combo aims to boost immune attack on liver tumors after radiation
NCT ID NCT04430452
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether giving immune-boosting drugs (durvalumab with or without tremelimumab) after standard radiation can shrink advanced liver cancer that has spread. About 21 adults whose cancer has progressed on or after prior immunotherapy will receive radiation followed by the drugs. The goal is to see if the combination triggers a stronger immune response against the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab (Imfinzi) and tremelimumab (immune-boosting drugs)
- What this could lead to
- If it works, this could offer a new treatment option for advanced liver cancer that has progressed after other immunotherapies.
- What could go wrong
- This is a small, early-phase trial with only 21 participants. The drugs may cause immune-related side effects, and the combination may not work better than radiation alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
- Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
- New drug zanzalintinib tested for advanced liver cancer
- New drug cocktail shows promise for tough liver cancer
- Home monitoring may keep cancer patients out of the ER